Latest News about NYSE:NNVC
Recent news which mentions NYSE:NNVC
NanoViricides updates progress on Phase 1a/1b clinical trial of antiviral drug candidate NV-387
November 29, 2023
Tags
NYSE:NNVC
From News Direct
Multi-Billion Dollar Treatment Market For Lung Infection That Causes Over 200,000 Hospitalizations Annually With Elderly, Young At Most Risk Has Game-Changing New Entrant
September 27, 2023
Tags
NYSE:NNVC
From News Direct
SARS-CoV-2 Is Not Done Yet — Could This New Drug In Clinical Trials Be The Safest Option For Treating COVID-19?
July 19, 2023
Tags
NYSE:NNVC
From News Direct
NanoViricides testing oral gummy and syrup Covid-19 treatment - Proactive Research Analyst
July 13, 2023
Tags
NYSE:NNVC
From News Direct
Tags
NYSE:NNVC
From News Direct
Tags
NYSE:NNVC
From News Direct
Tags
NYSE:NNVC
From News Direct
Tags
NYSE:NNVC
From News Direct
Tags
NYSE:NNVC
From News Direct
A Company With Solutions Against Emerging COVID Variants And Other Viral Infections To Combat Future Pandemic Threats
March 20, 2023
Tags
NYSE:NNVC
From News Direct
NanoViricides Reports Its Novel Monkeypox Antiviral Could Reach Clinical Status Rapidly
September 19, 2022
Tags
NYSE:NNVC
From News Direct
Monkeypox Is Popping Up In Places It Shouldn’t But NanoViricides Says It May Have A Solution
August 10, 2022
Tickers
SIGA
Tags
NYSE:NNVC
From News Direct
Tickers
NNVC
From InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.